KindredBio is revolutionizing therapeutic biologics, such as monoclonal antibodies and recombinant proteins.
Next Generation Therapeutics: Biologics
In humans, therapeutic biologics have revolutionized medicine, providing more effective treatments for many diseases, including various cancers and autoimmune disorders. KindredBio is developing next-generation veterinary therapeutic biologics for cats, dogs, and horses.
Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector. The inserted DNA codes for protein cause large quantities of recombinant protein to be produced through replication in living host cells. We purify the produced recombinant protein and administer it to the animal (cat, dog, or horse) for targeted therapy. This final preparation (drug formulation) is sterile and contains a highly pure and targeted drug. One recombinant protein commonly used in human medicine is erythropoietin alpha (Epogen®).